LIFECORE BIOMEDICAL, INC. DE
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2027 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $34.20M | $-0.19 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $31.10M | $-0.29 | – |
| Q4 FY2025 Ended May 25, 2025 | Aug 7, 2025 | During market hours | $36.40M | $-0.06 | – |
| Q3 FY2025 Ended Feb 23, 2025 | Apr 3, 2025 | During market hours | $35.20M | – | – |
| Q2 FY2025 Ended Nov 24, 2024 | Jan 2, 2025 | During market hours | $32.60M | – | – |
| Q1 FY2025 Ended Aug 25, 2024 | Aug 26, 2024 | During market hours | $37.90M | – | – |
| Q3 FY2024 Ended Feb 25, 2024 | Mar 20, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Aug 27, 2023 | Aug 31, 2023 | Before market open | $31.50M | $-1.11 | $-0.89 |
| Q4 FY2023 Ended May 28, 2023 | Jun 1, 2023 | Before market open | $27.60M | $-0.51 | $-0.22 |
| Q3 FY2023 Ended Feb 26, 2023 | Mar 16, 2023 | During market hours | $38.80M | $-0.42 | $-0.24 |
| Q1 FY2023 Ended Aug 28, 2022 | Oct 6, 2022 | Before market open | $43.40M | $-0.41 | $-0.32 |
| Q4 FY2022 Ended May 29, 2022 | Aug 10, 2022 | During market hours | $47.60M | $-1.22 | $-0.01 |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | calendar year 2026 | $20.50M to $25.00M | New |
| revenue | calendar year 2026 | $120.00M to $125.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Lifecore Biomedical, Inc. De filed with the SEC
Lifecore Biomedical to be Acquired by Webster Equity Partners
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
payments of $3.39 per share, based upon company achievement of performance milestones in 2028-2030 and assuming full performance milestone payments of $160 million in the aggregate . Upon completion
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
An Exciting Path Forward September 28, 2026 EXHIBIT 99.3
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026 , and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a high-performing, growth-focused, sterile injectable CDMO August 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026 , and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a high-performing, growth-focused, sterile injectable CDMO May 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Building a high-performing, growth-focused, sterile injectable CDMO March 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Building a high-performing, growth-focused, sterile injectable CDMO Jefferies Global Healthcare Conference November 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lifecore Biomedical Announces Special Stockholder Meeting
Other events · EX-99.1 to Form 8-K
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Executing Three-Pronged Growth Strategy Maximizing Existing Customer Business Advancing Programs Towards Commercialization Driving New Business 10
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
[email protected] Tim Brons (Media) 415-675-7402 [email protected] Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 [email protected] Source: Lifecore Biomedical, Inc.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
A New Era: Building Momentum for Sustainable Growth Investor Day November 21, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 [email protected]
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development and fill/finish of sterile injectable pharmaceutical products 4
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Lifecore Biomedical, Inc March 2024 Supplemental Financial Information FY23 10-K Restatement Summary Exhbit 99.2
Results of operations · EX-99.2 to Form 8-K
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods
Regulation FD disclosure · EX-99.1 to Form 8-K
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
LIFECORE BIOMEDICAL, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited and in thousands)
Results of operations · EX-99.1 to Form 8-K